Skip to main content

Adjuvant Hepatic Arterial Infusion Pump Chemotherapy Without Systemic Therapy After Repeat Local Treatment for Patients With Liver-only Recurrence of Colorectal Cancer

In brief

Liver-directed chemotherapy delivered 16.5 months' median liver disease-free survival

In 45 patients treated locally for liver-only colorectal cancer recurrence, hepatic artery pump chemotherapy without systemic therapy was followed by a median 16.5 months without liver recurrence, below the trial's prespecified 36-month efficacy target. Three-year overall survival was 71%, but serious treatment-related complications occurred, and the single-arm study cannot show whether this approach improves outcomes over other care.

Journal
Annals of surgery (Q1)
Published
10 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Loubna Outmani, Wills F Filipe, Florian E Buisman, Bas Groot Koerkamp, Karen Bolhuis, Leni van Doorn, et al.
PMID
43004518
DOI
10.1097/SLA.0000000000007247

Why clinicians should know about it

  • Picked for Surgical Oncology (top studies of the week, 15 November 2026): Adjuvant HAIP chemotherapy without systemic therapy after repeat local treatment

Abstract

BACKGROUND: Approximately 30% of patients develop liver-confined recurrences after local treatment for colorectal liver metastases (CRLM), which may be reduced by adjuvant therapy. Hepatic arterial infusion pump (HAIP) chemotherapy delivers high-dose liver-directed chemotherapy. OBJECTIVE: To investigate adjuvant HAIP chemotherapy without systemic therapy in patients with resectable liver-confined recurrence after prior local treatment of CRLM. METHODS: This multicenter, single-arm phase II trial enrolled patients with resectable recurrent CRLM across 3 centers in the Netherlands. Patients with prior or present extrahepatic disease were excluded. Adjuvant HAIP with floxuridine was administered up to 6 cycles. The primary endpoint was hepatic disease-free survival (hDFS) estimated using the Kaplan-Meier method, with a prespecified efficacy boundary of 36 months. RESULTS: Forty-five patients underwent local treatment followed by adjuvant HAIP chemotherapy without systemic therapy. Twenty-eight patients(62%) were treated for a first recurrent CRLM, and 17 patients for a second or higher. Twenty-five patients (56%) had ≥3 CRLM. All patients started HAIP chemotherapy, with a median of 6 cycles (interquartile range: 4 to 6). After a median follow-up of 38.7 months (95% CI: 33.0-42.3), the median hDFS was 16.5 months (95% CI: 9.1-25.8). The median progression-free survival was 14.0 months (95% CI: 7.7-23.0), and the 3-year overall survival was 71% (95% CI: 58%-87%). Initial recurrence included the liver in 23 patients (51%). HAIP implantation-related complications (Clavien-Dindo grade ≥3) occurred in 4 patients (9%), and HAIP chemotherapy-related complications (Common Terminology Criteria for Adverse Events grade ≥3) occurred in 6 patients (13%). Biliary sclerosis occurred in 4 patients; 3 required stent placement. CONCLUSION: Adjuvant HAIP chemotherapy without systemic therapy did not achieve the hypothesized hDFS in patients undergoing repeat local treatment for recurrent CRLM.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.